Madrigal Pharmaceuticals, Inc. (NasdaqGS: MDGL)
Health Care · Biotechnology · US
$471.83
+0.02% today · +10.3% 1Y
Madrigal Pharmaceuticals, Inc. (NasdaqGS: MDGL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.90B and employs 915 people.
Over the last twelve months the share price has gained 10.3%, trading between 393.61 and 615.00.
Tweenvest scores Madrigal Pharmaceuticals, Inc. across four factors: quality 37/100, value 86/100. Its strongest factor is value.
MDGL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.90B
- Revenue (TTM)
- $1.28B
- P/E
- —
- EPS
- -14.22
- Dividend yield
- —
- Beta (5Y)
- -1.05
- 52-week high
- $615.00
- 52-week low
- $393.61
- Avg volume (3M)
- —
- Shares outstanding
- 23.10M
- Employees
- 915
- Next earnings
- —
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- ISIN
- US5588681057
- Founded
- 2016
- Listed since
- Feb 6, 2007
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BridgeBio Pharma, Inc.NasdaqGS: BBIO | $12.78B | $65.90 | +0.84% |
| Halozyme Therapeutics, Inc.NasdaqGS: HALO | $12.53B | $111.91 | +1.35% |
| ALTEOGEN Inc.KOSDAQ: A196170 | $12.48B | ₩241,000.00 | -7.13% |
| ImmunityBio, Inc.NasdaqGS: IBRX | $11.14B | $10.14 | -3.52% |
| Vaxcyte, Inc.NasdaqGS: PCVX | $10.62B | $71.35 | -0.04% |
| BioMarin Pharmaceutical Inc.NasdaqGS: BMRN | $10.61B | $55.65 | +1.56% |
| Twist Bioscience CorporationNasdaqGS: TWST | $10.02B | $150.56 | -5.77% |
| Krystal Biotech, Inc.NasdaqGS: KRYS | $9.82B | $331.71 | +0.03% |
Figures last refreshed Oct 11, 2026.